Compare Applovin Corporation (APP) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Applovin Corporation vs Johnson & Johnson — how do they compare? Applovin Corporation trades at $305.74 (market cap $106.65B), while Johnson & Johnson trades at $260.91 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 5.9× Applovin Corporation's market cap, and Johnson & Johnson pays a 2.06% dividend while Applovin Corporation pays none. Which is the better fit depends on your goals.
| APP | JNJ | |
|---|---|---|
Market Cap | $106.65B | $626.09B |
Sector | Technology | Health |
52-Week High | $733.60 | $267.24 |
52-Week Low | $318.68 | $172.78 |
Enterprise Value | $107.11B | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AppLovin (APP) trades at $310.95, down 8.27% over 24 hours, reflecting recent bearish momentum after a Q2 2026 earnings miss. The stock shows strong profitability with a 64.58% net income margin and robust revenue growth of 53% YoY in Q2, but faces technical pressure with a bearish signal from moving averages. Recent news highlights a Bank of America downgrade to Neutral on August 11, 2026, citing uncertainty around sustaining 30% revenue growth, contributing to the stock's decline.
The outlook is mixed: strong fundamentals and an 80.77% analyst buy rating with a $556.53 consensus price target suggest upside, but execution risks and technical weakness pose near-term challenges. Investors should weigh high valuation multiples against growth sustainability concerns.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
